Purpose. Artificial tears are widely used in the treatment of dry eye disease, although current formulations do not closely resemble natural tears. The purpose of this study was the design and characterization of a novel in situ gelling artificial tear formulation, containing both lipid and aqueous components, in order to resemble natural tears and replenish the tear film.
HIGHLIGHTS
▪ A novel liposome-based, in situ gelling artificial tear formulation was developed.
▪ Physicochemical properties, in vitro and in vivo tolerance were evaluated.
▪ The formulation showed suitable properties for topical ophthalmic administration.
▪ Good in vitro and in vivo tolerance was observed.
▪ The novel artificial tear may be beneficial in the treatment of dry eye disease.
INTRODUCTION

Dry eye disease (DED) is a highly prevalent health problem affecting approximately 5-35%
of the world's population [1] . It is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability [2] .
DED is associated with a significant adverse impact on vision-related quality of life, causing difficulties in daily activities [3, 4] . It can be caused by various factors such as meibomian gland dysfunction, low blink rate, ocular surface disorders and contact lens wear, among others, resulting in the alteration of the tear film [2] .
Artificial tears are widely used for mild to moderate dry eye, and can be prescribed in combination with other therapies for moderate to severe dry eye. Numerous artificial tear formulations with a diverse range of components are currently available in the market; however, most of these formulations do not quite resemble the composition of natural tears [5] . Furthermore, they have a short ocular residence time and require repeated daily administration.
An ideal artificial tear formulation should contain both aqueous and lipid components to mimic natural tears, and have certain physicochemical properties such as hypotonicity or isotonicity, neutral to slightly alkaline pH, suitable surface tension and viscosity [6] . A surface tension near the physiological range of natural tears, that is reported to be 40-46 mN/m [7, 8] , provides a good spreading of the formulation over the ocular surface. For artificial tears that follow Newtonian behavior, the desirable viscosity would be in the physiological range of 1.0-8.3 mPa.s [9, 10] ; whereas for those that follow non-Newtonian behavior, a dynamic viscosity in the same range would be suitable. Additionally, an ideal artificial tear formulation should be well tolerated on the ocular surface, provide extended ocular residence time, and be preservative-free. This study aimed at designing a novel liposome-based and in situ gelling artificial tear formulation having such properties to replenish the tear film, with potential beneficial effects for the treatment of DED. 
MATERIALS AND METHODS
Materials
Preparation of the artificial tear formulation
Liposomes were prepared by the thin-film hydration method described by Bangham et al.
[11] and modified by Vicario-de-la-Torre et al. [12] . 400 mg of phosphatidylcholine ( International Ltd., Kent, UK) with a pore size of 0.2 μm.
The liposomal suspension was diluted with solutions of gellan gum, hydroxypropyl methylcellulose (HPMC), levocarnitine (L-carnitine), sodium chloride (NaCl) and potassium chloride (KCl) to obtain the final artificial tear formulation ( Table 1 ). The preparation was performed under aseptic conditions. The aqueous medium, polymer and electrolyte solutions underwent steam sterilization, whereas the L-carnitine solution was sterilized by filtration. 
Characterization of the artificial tear formulation
The particle size and the size distribution profile of liposomal nanoparticles were determined at room temperature by dynamic light scattering (Microtrac ® Zetatrac™ Particle Size & Zeta Potential Analyzer, Microtrac Europe GmbH, Meerbusch, Germany).
The pH of the formulation was determined at room temperature with a calibrated pH meter (GLP 22, Crison Instruments S.A., Barcelona, Spain). The surface tension was measured with a tensiometer (Krüss K-11 Tensiometer, Krüss GmbH, Hamburg, Germany) according to the Wilhelmy plate method. Measurements were performed at 33°C, which corresponds to the temperature of the ocular surface. The viscosity of the artificial tear was determined with a rheometer (HAAKE RheoStress 1, ThermoFisher Scientific), using the parallel plate system (plate diameter 60 mm, separation 0.5 mm) at 33°C. The shear rate was increased in 20 steps from 0 to 1000 s -1 . All measurements were performed in triplicate.
In vitro tolerance studies
The in vitro tolerance of the formulation was assessed by means of cell viability measurements in a human epithelial carcinoma cell line (HeLa) and a murine macrophage cell line (J774). Cellular reduction of the tetrazolium salt MTT to formazan [13] was evaluated after cells were exposed to the formulation for 2 hours.
In vivo tolerance studies
The in vivo tolerance studies were performed in six male New Zealand white rabbits; 30 μL of the artificial tear was administered in the right eye of each animal every 30 minutes for 6 hours, whereas the contralateral eye received the same volume of isotonic saline solution and served as control. Macroscopic evaluation of the ocular surface and the clinical signs was performed before the first instillation, and at 3, 6, and 24 hours after the first instillation, in compliance with the protocol described by Enríquez de Salamanca et al. [14] . Corneal opacity, conjunctival alterations, discharge, eyelid swelling, and animal discomfort as evident by intense blinking were examined and graded from 0 to 2.
RESULTS
Characterization of the artificial tear formulation
The results obtained in the characterization of the physicochemical properties of the artificial tear are reported in Table 2 . Data were expressed as mean ± standard deviation (SD). The liposomal nanoparticles of the formulation showed a unimodal size distribution ( Figure   1 ). The rheological properties of the artificial tear followed Newtonian behavior (Figure 2 ). 
In vivo tolerance studies
Prior to the experiment, all of the six animals had a normal ocular surface and showed no clinical signs or discomfort. During the experiment, the animals showed neither discomfort nor clinical signs (grade 0) within 24 hours after the first instillation of the artificial tear. 
DISCUSSION
DED is associated with alterations and instability of the tear film; therefore, restoring the tear film is fundamental in its management. This study aimed at developing a novel artificial tear formulation that resembles natural tears and replenishes the tear film. Liposomes, consisting of PC and Chol, were employed to replenish the lipids of the tear film. The in situ gelling polymer gellan gum was incorporated because of its unique gel-forming property when in contact with certain ions present in tears [15] [16] [17] [18] , with the aim of resisting the natural drainage and extending the ocular residence time of the formulation. HPMC was used to provide bioadhesion [19] and increase the ocular residence time. Antioxidants vit A and vit E, and osmoprotectants L-carnitine and trehalose were incorporated to enhance the potential efficacy of the artificial tear in the treatment of DED.
When formulating an artificial tear, the key physicochemical parameters such as pH, surface tension, and viscosity should be taken into consideration. Human tears have a pH of 7.0-7.5 [20, 21] , and a buffering capacity that prevents the ophthalmic formulations within the pH range of 6.6-9.0 from causing discomfort [22] [23] [24] . The surface tension of natural tears is reported to be 40-46 mN/m [7, 8] , and the viscosity 1.0-8.3 mPa.s [9, 10] . The surface tension of an ophthalmic formulation affects its interaction with the tear film and spreading ability over the ocular surface [25] . The viscosity, if excessively high, can cause non-uniform mixing of the formulation with natural tears, blurred vision and discomfort. The physicochemical properties of the artificial tear developed in this study, namely the slightly alkaline pH (7.6), a viscosity in the physiological range of natural tears (4.0 mPa.s), and a surface tension close to that of natural tears (53.4 mN/m), all together suggest good spreading of the formulation over the ocular surface without causing tear film instability, blurred vision or discomfort. Furthermore, the liposomal nanoparticles of the artificial tear had a suitable size for a topical ophthalmic formulation.
The artificial tear demonstrated absence of toxicity in both HeLa and J774 cell lines. The formulation did not cause any discomfort or clinical signs in rabbits, indicating good in vivo tolerance.
In conclusion, the results obtained in this study demonstrated that the liposome-based in situ gelling artificial tear formulation presents suitable properties for topical ophthalmic administration and is well tolerated. Due to its potential of replenishing the tear film lipids, restoring the tear film, and protecting the corneal epithelium, the novel artificial tear developed in this study may be beneficial in the treatment of DED.
